ストックスクリーナーアプリを入手
5.27
5.22%
-0.29
プレマーケット:
5.66
0.39
+7.40%
Climb Bio Inc (CLYM) 最新ニュース
Piper Sandler initiates Climb Bio stock with Overweight rating, $23 target - Investing.com UK
Climb Bio Teases 5 Data Readouts in 2026, Highlights CD19 and APRIL “Sweeper” Programs at Summit - MarketBeat
CLYM: Five clinical readouts in 2024 and strong cash runway drive autoimmune pipeline progress - TradingView
Climb Bio, Inc. (NASDAQ:CLYM) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Climb Bio to Present at Upcoming Investor Conferences - The Manila Times
Top High Flyer Healthcare Stocks Revealed - Intellectia AI
Cheap high flyer healthcare stockshigh momentum and low valuation (CLYM:NASDAQ) - Seeking Alpha
Activity Recap: Can Barings BDC Inc weather a recessionPortfolio Update Report & Weekly Watchlist of Top Performers - baoquankhu1.vn
Day Trade: Can Climb Bio Inc sustain its profitabilityPortfolio Performance Report & Accurate Trade Setup Notifications - baoquankhu1.vn
Tech Rally: Will Vishay Precision Group Inc announce a stock split2025 Big Picture & Capital Protection Trade Alerts - baoquankhu1.vn
Aug Macro: Can Climb Bio Inc outperform in the next rallyLayoff News & Daily Chart Pattern Signals - baoquankhu1.vn
Zag Bio Appoints Jan Hillson, M.D., as Chief Medical Officer - Business Wire
Climb Bio, Inc. (NASDAQ:CLYM) Shares Could Be 45% Below Their Intrinsic Value Estimate - Yahoo Finance
Ten new option listings and two option delistings on January 22nd - TipRanks
HubSpot, Inc. (HUBS) Stock Analysis: Can It Climb 86.84% To Meet Analysts' Targets? - directorstalkinterviews.com
Climb Bio, Inc. (NASDAQ:CLYM) Short Interest Update - MarketBeat
ImmunityBio shares climb as bladder cancer trial nears full enrollment, BLA submission expected by year end - Seeking Alpha
ImmunityBio shares climb 3% premarket after company's prelim quarterly revenue exceeds estimates - marketscreener.com
Analysts Are Bullish on Top Healthcare Stocks: Climb Bio (CLYM), Travere Therapeutics (TVTX) - The Globe and Mail
Resistance Check: How Climb Bio Inc stock benefits from tech adoption2025 Bull vs Bear & Long-Term Growth Portfolio Plans - Bộ Nội Vụ
Patterns Watch: How Climb Bio Inc stock benefits from tech adoption2025 Trading Volume Trends & Weekly Hot Stock Watchlists - Bộ Nội Vụ
Winners Losers: Is Climb Bio Inc stock positioned well for digital economyJuly 2025 PostEarnings & Daily Profit Maximizing Trade Tips - Bộ Nội Vụ
Bull Bear: Is Climb Bio Inc stock positioned well for digital economyJuly 2025 Chart Watch & High Conviction Buy Zone Picks - Bộ Nội Vụ
Laser Focus WorldClimb Bio to Present at Upcoming September 2025 Investor Conferences - FinancialContent
Climb Bio, Inc. (NASDAQ:CLYM) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Update Report: Why analysts upgrade Climb Bio Inc stockJuly 2025 Review & Real-Time Buy Signal Notifications - moha.gov.vn
Can Climb Bio Inc. stock deliver sustainable ROEMarket Trend Review & Weekly Top Gainers Trade List - ulpravda.ru
Climb Bio advances clinical trials with first patients dosed in key studies - Investing.com Nigeria
Analysts Offer Insights on Healthcare Companies: Climb Bio (CLYM) and Halozyme (HALO) - The Globe and Mail
Climb Bio’s CLYM116 Moves Into First-in-Human Testing: What Early Investors Should Watch - TipRanks
Climb Bio initiated with a buy at Freedom Capital - MSN
Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026 - Sahm
Is Climb Bio Inc. stock oversold or undervaluedProfit Target & Low Risk High Reward Ideas - Улправда
Analyst Downgrade: Can Climb Bio Inc. stock maintain growth trajectoryJuly 2025 Summary & Low Risk Growth Stock Ideas - Улправда
How Climb Bio Inc. stock reacts to oil pricesTreasury Yields & Free Weekly Watchlist of Top Performers - Улправда
Climb Bio outlines 2026 clinical milestones and cash runway - TipRanks
Climb Bio advances clinical trials with first patients dosed in key studies By Investing.com - Investing.com South Africa
Pasadena Star-News: Local News, Sports, Things to DoClimb Bio, Inc.Common Stock (Nasdaq:CLYM) Stock Quote - FinancialContent
Climb Bio reports inducement grant under Nasdaq listing rule - MSN
Climb Bio, Inc.Common Stock (NQ: CLYM - markets.financialcontent.com
Climb Bio (NASDAQ:CLYM) Director Purchases $24,888.50 in Stock - MarketBeat
Alumis reports positive phase 3 results for psoriasis drug By Investing.com - Investing.com Australia
Climb Bio (CLYM) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Climb Bio Inc Stock Analysis and ForecastSector Performance Review & Explosive Capital Growth Plans - Early Times
Alumis issues breach notice to Climb Bio over $3 million milestone payment - Investing.com India
Setup Watch: Will SBUX stock benefit from commodity pricesPortfolio Value Summary & AI Driven Price Forecasts - moha.gov.vn
Climb Bio appoints Edgar D. Charles as Chief Medical Officer - MSN
Alumis IncCo & Its Unit Issues Notice Of Material Breach & Notification Of Claim For Indemnification To Climb BioSEC Filing - TradingView — Track All Markets
Alumis issues breach notice to Climb Bio over $3 million milestone payment By Investing.com - Investing.com South Africa
Alumis Inc. Issues Notice of Material Breach to Climb Bio - TradingView — Track All Markets
Climb Bio challenges Alumis milestone and royalty obligations - MSN
HC Wainwright forecasts 2026 data readouts for Climb Bio’s (CLYM) Budoprutug across clinical tracks - MSN
Climb Bio files complaint against Alumis and AcelyrinSEC filing - MarketScreener
Climb Bio Challenges Alumis Milestone and Royalty Obligations - TipRanks
Climb Bio, Inc. Files Legal Complaint Over Asset Purchase Agreement - TradingView — Track All Markets
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):